By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Immutep S.A. 

Parc Club Orsay, 2, Rue Jean

Rostand  Orsay  92296  France
Phone: n/a Fax:


SEARCH JOBS



Segment
Start Up





Company News
Immutep S.A. And Eddingpharm (Cayman) Inc. Start Production Of Immufact® IMP321 At WuXi AppTec, Inc. In China 4/8/2014 1:36:01 PM
Immutep S.A. and Eddingpharm (Cayman) Inc. Sign Agreement for Development of ImmuFact® IMP321 in China 10/7/2013 9:25:53 AM
Immutep S.A. and Lonza Inc. Sign Agreement for Cell Line Selection, Cell Banking and Process Development of ImmuFact(R) IMP321 4/10/2012 11:23:20 AM
Immutep S.A. and GlaxoSmithKline (GSK) Sign Licence Agreement for IMP731, a Novel Therapeutic Antibody for the Treatment of Autoimmune Diseases 1/6/2011 11:09:35 AM
Immutep S.A. Announces Final Results in Phase I/II Chemoimmunotherapy Trial in Metastatic Breast Cancer 9/7/2010 1:54:45 PM
Immutep S.A. Announces Oral Presentation At American Society of Clinical Oncology Annual Meeting Of IMP321 Final Results In Phase I/II Chemoimmunotherapy Trial 5/19/2010 10:59:14 AM
Immutep S.A. Announces Final Results In Phase I/II Chemoimmunotherapy Trial In Breast Cancer 1/4/2010 10:52:45 AM
Immutep S.A. Announces New Interim Results In Phase I/II Chemoimmunotherapy Trial In Breast Cancer 10/6/2009 2:05:45 PM
Immutep S.A. Announces Final Results In Advanced Renal Cell Carcinoma 9/29/2009 1:20:24 PM
Immutep S.A. Announces Start of Clinical Trial in Pancreatic Cancer 4/15/2009 11:44:11 AM
12
//-->